... ARCON: Accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC. ... ...
NBII National Biological Information Infrastructure
... of a phase I/II study (16), and non-small cell lung cancer (17) and glioblastoma (18) trials were not encouraging. ... ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung...
PURPOSE: To report the acute toxicity profile and compliance from a randomized Phase III trial comparing accelerated radiotherapy (AR) with accelerated radiotherapy plus carbogen and nicotinamide (ARCON) in laryngeal cancer. METHODS AND MATERIALS: From April 2001 to February 2008, 345 patients ...
PubMed
Purpose: We previously showed that accelerated radiotherapy combined with carbogen and nicotinamide (ARCON) was an effective approach to use in the radical treatment of patients with advanced bladder carcinoma. Interim analysis from this Phase II study showed that it achieved a high level of locoregional control and overall survival ...
Energy Citations Database
The 40-year history of hypoxic cell sensitisation can be traced from hyperbaric oxygen to the present clinical studies with carbogen, nicotinamide and accelerated radiotherapy. A meta-analysis by Overgaard (1995) included 10703 cases entered into 83 randomised controlled trials and showed an overall improvement in local tumour control ...
PubMed Central
Purpose: To evaluate the prognostic significance of hemoglobin (Hb) levels measured before and during treatment with accelerated radiotherapy with carbogen and nicotinamide (ARCON). Methods and Materials: Two hundred fifteen patients with locally advanced tumors of the head and neck were included in a phase II trial of ARCON. This ...
Tumour tissue oxygenation has been measured in man during carbogen breathing (95% O2, 5% CO2) using a commercially available polarographic electrode system (Eppendorf p02 histograph). At least 200 tumour measurements in each of 17 patients with accessible tumours were taken before, and subsequently continuously after the commencement of carbogen breathing ...
The effect of hyperoxygenation with carbogen (95% O(2) + 5% CO(2)) inhalation on RIF-1 tumor pO(2) and its consequence on growth inhibition with fractionated radiotherapy is reported. The temporal changes in the tumor pO(2) were assessed by in vivo Electron Paramagnetic Resonance (EPR) oximetry in mice breathing 30% O(2) or carbogen ...
The purpose of this study was to investigate the feasibility of using Fluosol-DA 20% in combination with carbogen inhalation to improve the radiotherapy of SCK tumors in A/J mice. The effect of i.v. injected Fluosol-DA and carbogen inhalation on the response of tumors to single and fractionated irradiation, and that on the changes in ...
Hypoxia has been associated with poor local tumour control and relapse in many cancer sites, including carcinoma of the prostate. This translational study tests whether breathing carbogen gas improves the oxygenation of human prostate carcinoma xenografts in mice and in human patients with prostate cancer. A total of 23 DU145 tumour-bearing mice, 17 PC3 tumour-bearing mice and ...
... Descriptors : *LINEAR ACCELERATORS, *MEDICAL EQUIPMENT, ELECTRON ACCELERATORS, RADIOTHERAPY, ELECTRON BEAMS ...
DTIC Science & Technology
Carbogen (95% O[sub 2] + 5% CO[sub 2]) increases the radiation response of tumors and reduced dose rate irradiation spares the damage of normal tissues. The purpose in this paper is to investigate the possibility of selective radiosensitization of tumors by reduced dose rate irradiation in combination with carbogen inhalation. SCCVII tumors in C3H/He mice ...
Purpose: Lack of methods for repeated assessment of tumor pO{sub 2} limits the ability to test and optimize hypoxia-modifying procedures being developed for clinical applications. We report repeated measurements of orthotopic F98 tumor pO{sub 2} and relate this to the effect of carbogen inhalation on tumor growth when combined with hypofractionated ...
Most experimental tumours contain experimental hypoxic cells located either far from the vessels or close to collaped vessels. The radioresistance of these cellscan be reduced by different treatments and, the best one will depend on the proportion of cells in the two categories of hypoxia. In patients, hypoxic areas have been detected in most solid tumours. The outcome of hypoxia during the course ...
NASA Astrophysics Data System (ADS)
The physical, mechanical and dosimetric features of betatrons are described and discussed. Reference is also made to difficulties that may arise and the limitations associated with their employment as electron accelerators in radiotherapy. PMID:828281
... treatment for this possible cause is called carbogen inhalation. Carbogen is a mixture of oxygen and carbon ... better inside the ear. Like steroid therapy, carbogen inhalation does not help every patient, but some SSHL ...
MedlinePLUS
This paper outlines technological considerations in the design of accelerator facilities for medical applications. Emphasis is placed on the specific requirements for MARIA, a radioisotope and radiotherapy facility being planned in Edmonton, Canada. The m...
National Technical Information Service (NTIS)
... data, the effect of nicotinamide and carbogen on brain tumors appears to be limited (20, 38). However, continued use of carbogen and nicotinamide in treatment of specific tumors such head and neck tumors a...
Purpose: Tumor hypoxia is a well-known therapeutic problem; however, a lack of methods for repeated measurements of glioma partial pressure of oxygen (pO{sub 2}) limits the ability to optimize the therapeutic approaches. We report the effects of 9.3 Gy of radiation and carbogen inhalation on orthotopic 9L and C6 gliomas and on the contralateral brain pO{sub 2} in rats using a ...
PurposeTumor hypoxia is a well-known therapeutic problem; however, a lack of methods for repeated measurements of glioma partial pressure of oxygen (pO2) limits the ability to optimize the therapeutic approaches. We report the effects of 9.3 Gy of radiation and carbogen inhalation on orthotopic 9L and C6 gliomas and on the contralateral brain ...
Continuous, hyperfractionated, accelerated radiotherapy (CHART) was devised to give the maximum chance of improving clinical radiotherapy and was based upon available radiobiological evidence. A pilot study, begun in 1985, has now included 210 patients. When comparison is made with previously treated cases, improved results have been ...
Continuous, hyperfractionated, accelerated radiotherapy (CHART) has given high levels of tumour control in advanced head and neck and bronchial carcinomas. In general, late changes have appeared less than after conventional radiotherapy but despite a prediction of reduced risk of spinal cord damage, two cases of radiation myelitis have ...
